Sarepta Therapeutics, Inc.
SRPT
$16.66
$0.261.59%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -57.18% | -191.39% | 144.00% | -381.36% | 373.21% |
| Total Depreciation and Amortization | -71.53% | 70.20% | 8.64% | -4.56% | 6.62% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -60.66% | 4,226.70% | -97.00% | 185.83% | -53.63% |
| Change in Net Operating Assets | 1,261.59% | -159.01% | 117.58% | -125.43% | 42.30% |
| Cash from Operations | 999.60% | -105.58% | 144.79% | -733.85% | 230.19% |
| Capital Expenditure | 84.34% | 27.87% | 27.16% | -14.62% | -2.20% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -60.91% | 298.92% | 125.86% | -130.86% | 976.13% |
| Cash from Investing | -58.60% | 621.49% | 111.06% | -138.11% | 693.14% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 71.65% | -40,670.07% | 90.53% | -4,620.59% | -- |
| Issuance of Common Stock | -98.55% | 1,314.27% | -90.43% | 322.67% | -73.03% |
| Repurchase of Common Stock | -- | 100.00% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 70.90% | -- | -- | -- | -- |
| Cash from Financing | 66.71% | -394.56% | -290.98% | -74.54% | 256.12% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 88.16% | -62.92% | 131.29% | -195.25% | 587.25% |